Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm.
作者信息
Walia Anushka, Prasad Vinay
机构信息
School of Medicine, University of California, San Francisco, CA, USA.
Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
出版信息
Blood Cancer J. 2023 Mar 15;13(1):36. doi: 10.1038/s41408-023-00811-z.
Abstract
摘要
相似文献
1
Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm.当前慢性粒细胞白血病指南过度强调第二代酪氨酸激酶抑制剂：重新审视这一范式。
Blood Cancer J. 2023 Mar 15;13(1):36. doi: 10.1038/s41408-023-00811-z.
2
Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.酪氨酸激酶抑制剂时代的慢性髓性白血病：分子靶向治疗的不断演变模式
Mol Diagn Ther. 2016 Aug;20(4):315-33. doi: 10.1007/s40291-016-0208-1.
3
[Research Advance of Mutation and the Efficacy of Second and Third Generation TKI in Chronic Myeloid Leukemia--Review].[慢性髓性白血病中第二代和第三代酪氨酸激酶抑制剂的突变与疗效研究进展——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Apr;31(2):585-588. doi: 10.19746/j.cnki.issn.1009-2137.2023.02.040.
4
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.BCR-ABL 酪氨酸激酶抑制剂治疗费城染色体阳性慢性髓性白血病：综述。
Leuk Res. 2010 Oct;34(10):1255-68. doi: 10.1016/j.leukres.2010.04.016.
5
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.新型复合突变导致慢性髓性白血病对多种酪氨酸激酶抑制剂耐药的发现及蛋白建模研究。
Asian Pac J Cancer Prev. 2020 Dec 1;21(12):3517-3526. doi: 10.31557/APJCP.2020.21.12.3517.
6
Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.抑制自噬：增强慢性髓系白血病干细胞对酪氨酸激酶抑制剂敏感性的新策略。
Leuk Lymphoma. 2011 Feb;52 Suppl 1(Suppl 1):54-9. doi: 10.3109/10428194.2010.546913. Epub 2011 Jan 21.
7
Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.BCR-ABL TKIs 耐药机制及治疗策略：综述。
Crit Rev Oncol Hematol. 2015 Mar;93(3):277-92. doi: 10.1016/j.critrevonc.2014.11.001. Epub 2014 Nov 13.
8
Designing Novel BCR-ABL Inhibitors for Chronic Myeloid Leukemia with Improved Cardiac Safety.设计新型 BCR-ABL 抑制剂用于慢性髓性白血病并改善心脏安全性。
J Med Chem. 2022 Aug 25;65(16):10898-10919. doi: 10.1021/acs.jmedchem.1c01853. Epub 2022 Aug 9.
9
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.ABL 酪氨酸激酶抑制剂在慢性髓性白血病细胞中的阈值水平决定了它们向细胞凋亡的趋化性。
Cancer Res. 2013 Jun 1;73(11):3356-70. doi: 10.1158/0008-5472.CAN-12-3904. Epub 2013 Apr 10.
10
Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.用于克服Bcr-Abl/T315I的Abl酪氨酸激酶抑制剂：从第二代到第三代
Expert Rev Anticancer Ther. 2008 Sep;8(9):1387-98. doi: 10.1586/14737140.8.9.1387.
引用本文的文献
1
Bilateral visual loss as the initial presentation of chronic myeloid leukemia: a case report.双侧视力丧失作为慢性髓性白血病的初始表现：一例报告
Ann Med Surg (Lond). 2024 Sep 12;86(10):6335-6339. doi: 10.1097/MS9.0000000000002570. eCollection 2024 Oct.
2
Targeted degradation of oncogenic BCR-ABL by silencing the gene of NEDD8 E3 ligase RAPSYN.通过沉默 NEDD8 E3 连接酶 RAPSYN 的基因来靶向降解致癌的 BCR-ABL。
J Nanobiotechnology. 2024 May 13;22(1):247. doi: 10.1186/s12951-024-02505-5.
本文引用的文献
1
Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia.第一代与第二代酪氨酸激酶抑制剂作为慢性髓性白血病一线治疗时的治疗中断与方案变更
J Health Econ Outcomes Res. 2015 Apr 27;2(2):181-191. doi: 10.36469/9899. eCollection 2015.
2
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor.酪氨酸激酶抑制剂治疗 2 年后仍未达到主要分子缓解的慢性髓性白血病。
Am J Hematol. 2023 Apr;98(4):639-644. doi: 10.1002/ajh.26836. Epub 2023 Jan 16.
3
Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?哪种酪氨酸激酶抑制剂应被选作慢性期慢性髓性白血病的一线治疗药物？
Cancers (Basel). 2021 Oct 12;13(20):5116. doi: 10.3390/cancers13205116.
4
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.一线尼洛替尼对比伊马替尼治疗初诊慢性期慢性髓性白血病的长期疗效：ENESTnd 研究 10 年分析。
Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7.
5
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?酪氨酸激酶抑制剂在慢性髓性白血病中的停药：何时及针对谁？
Haematologica. 2020 Dec 1;105(12):2738-2745. doi: 10.3324/haematol.2019.242891.
6
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.EUTOS 长期生存（ELTS）评分优于 Sokal 评分，可预测慢性髓性白血病的生存情况。
Leukemia. 2020 Aug;34(8):2138-2149. doi: 10.1038/s41375-020-0931-9. Epub 2020 Jun 29.
7
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.一线伊马替尼与第二代和第三代酪氨酸激酶抑制剂用于慢性期慢性粒细胞白血病的疗效比较：一项系统评价和荟萃分析。
Blood Adv. 2020 Jun 23;4(12):2723-2735. doi: 10.1182/bloodadvances.2019001329.
8
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.与伊马替尼相比，第二代BCR-ABL1酪氨酸激酶抑制剂在慢性髓性白血病患者中实现无治疗缓解的治疗价值：一项建模研究
Lancet Haematol. 2019 Aug;6(8):e398-e408. doi: 10.1016/S2352-3026(19)30087-0. Epub 2019 Jun 14.
9
Imatinib is still recommended for frontline therapy for CML.伊马替尼仍被推荐用于 CML 的一线治疗。
Blood Adv. 2018 Dec 26;2(24):3648-3652. doi: 10.1182/bloodadvances.2018018614.
10
Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death.特别考虑死亡竞争原因的慢性髓性白血病患者的预后评分
Ann Hematol. 2015 Apr;94 Suppl 2:S209-18. doi: 10.1007/s00277-015-2316-0. Epub 2015 Mar 27.
Zotero 插件